Table 5.

Main data regarding adjuvant chemotherapy for gastric cancer

Ref.	Study design	n	Survival	Disease free	Recurrence (P value)	Loco-regional
			(P value, HR, RR)	Survival (P value, HR, RR)		Recurrence (P value)
Sakuramoto et al[59], 2007	RCT	S: 530	At 3 yr	At 3 yr	At 3 yr	At 3 yr
	Surgery alone (S) vs surgery + chemoterapy (SC)	SC: 529	S < SC (0.003)	S < SC (0.001)	S > SC (0.001)	S > SC (0.006)
Sasako et al[60], 2011	RCT	S: 530	At 5 yr	At 5 yr	At 5 yr	At 5 yr
	Surgery alone (S) vs surgery + chemoterapy (SC)	SC: 529	SC benefit vs S	SC benefit vs S	S > SC (0.008)	S > SC (0.005)
			HR = 0.66	HR = 0.65
Bang et al[61], 2012	RCT	S: 515	At 3 yr	At 3 yr	At 3 yr	At 3 yr
	Surgery alone (S) vs surgery + chemoterapy (SC)	SC: 520	SC benefit vs S	SC benefit vs S	S > SC (0.0006)	S > SC (0.0003)
			HR = 0.72 (0.049)	HR = 0.56 (0.0001)
Liu et al[64], 2008	Meta-analysis	S: 2313	At median 5 yr	At median 5 yr	At median 5 yr	At median 5 yr
	Surgery alone (S) vs	SC: 2286	SC benefit vs S	SC benefit vs S	SC benefit vs S	SC benefit vs S
	surgery + chemoterapy (SC)		RR = 0.85 (0.00001)	RR = 0.85 (0.04)	RR = 0.78	RR between 0.62-0.65
Sun et al[62], 2009	Meta-analysis	S: 1914	At 5 yr
	Surgery alone (S) vs surgery + chemoterapy (SC)	SC: 1931	SC benefit vs S
			HR = 0.78 (0.001)
Paoletti et al[63], 2010	Meta-analysis	S: 1885	At 10 yr	At 10 yr
	Surgery alone (S) vs surgery + chemoterapy (SC)	SC: 1953	SC benefit vs S	SC benefit vs S
			HR = 0.82 (0.001)	HR = 0.82 (0.001)

RCT: Randomized controlled trial.